Posts by: Alice Melão

Alice Melão

February 12, 2019February 12, 2019

Direct Nerve Stimulation Using MyoRegulator System Seen to Reduce Spasticity in Mice with Spinal Injury

News

Treatment with PathMaker Neurosystems’ anodal trans‐spinal direct current stimulation (tsDCS), a non-invasive direct nerve stimulation tool called MyoRegulator, was found to effectively ease spasticity in mice with spinal cord injury, a ... Read more

February 1, 2019February 7, 2019

Study Shows Benefits of Low Temperature Exercise for MS Patients

News

Reducing body temperature during physical exercise can help rewire the brain and improve motor control in patients with multiple sclerosis (MS), a new research study at Canada’s Memorial University shows. ... Read more

January 31, 2019January 31, 2019

MS Patients Sought to Test Alternative Chronic Pain Treatment Methods

News

A clinical trial funded by the National Multiple Sclerosis Society is recruiting adult patients with multiple sclerosis (MS) to test two non-pharmacological strategies to manage MS-related chronic pain. The ... Read more

January 21, 2019January 28, 2019

Herbicide Called Linuron Seen to Trigger Inflammatory Signals Linked to MS in Study

News

The herbicide linuron, commonly used with other herbicides, insecticides and fungicides to control the growth of grass and weeds, may be an important environmental risk factor in the development ... Read more

January 15, 2019January 15, 2019

UK Experts Propose New Guidelines to Treat Women with MS Before, During, After Pregnancy

News

Multiple sclerosis (MS) experts in the United Kingdom have proposed consensus guidelines for the management and treatment of pregnant women with the disease, and couples affected by MS who ... Read more

January 11, 2019January 11, 2019

WeHealth, PathMaker Collaborating to Develop MyoRegulator as Noninvasive Treatment for Spasticity

News

WeHealth by Servier and PathMaker Neurosystems have established a new partnership to develop and commercialize the first neuromodulation technology for noninvasive treatment of spasticity, the companies announced. The agreement establishes ... Read more

January 11, 2019January 14, 2019

Mavenclad Approved for Reimbursement as RRMS Treatment in Australia

News

Australia was one of the first countries to approve the use of Mavenclad (cladribine tablets, 10 mg) to treat patients with highly active relapsing-remitting multiple sclerosis (RRMS). Now, the country’s ... Read more

January 9, 2019January 9, 2019

Five Finalists Vie for $1 Million Prize in Mobility Unlimited Challenge

News

Five finalists remain in the running for the $1 million prize being offered in the Mobility Unlimited Challenge, a global competition to promote the development of innovative solutions for personal ... Read more

January 7, 2019January 7, 2019

More Effort Needed to Recruit Minorities to Phase 3 Clinical Trials, MS Expert Says

News

Because multiple sclerosis (MS) presentation and progression course can be very different between people of African ancestry and Caucasians, the recruitment of minorities to Phase 3 clinical trials is ... Read more

December 20, 2018December 20, 2018

Cannabis-based Sublingual Tablet to Enter Trials in Israel as Possible Spasticity Treatment, OWCP Says

News

OWC Pharmaceutical Research is planning new clinical studies to evaluate the activity and safety of its cannabinoid-enriched sublingual soluble tablet. The company announced that an Institutional Review Board (IRB) in ... Read more

December 18, 2018December 18, 2018

FDA Asked to Approve Diroximel Fumarate as Oral Treatment for Relapsing MS

News

Alkermes filed a request for the approval of diroximel fumarate (BIIB098) to treat relapsing forms of multiple sclerosis (MS) with the U.S. Food and Drug Administration (FDA). If approved, diroximel fumarate ... Read more

December 12, 2018December 12, 2018

Ocrevus Now Available Through NHS Scotland to Treat RRMS

News

Ocrevus (ocrelizumab, by Genentech) is now available through the National Health System (NHS) of Scotland to treat patients with relapsing-remitting multiple sclerosis (RRMS). The decision by the Scottish Medicines ... Read more

December 11, 2018December 11, 2018

WUSTL Team Receives $6.3 Million Grant to Develop PET Scan Tracers

News

The Washington University School of Medicine in St. Louis (WUSTL) will create a new research center to investigate and advance the development of tracers for positron emission tomography (PET) scans. ... Read more

November 30, 2018December 13, 2018

Gilenya Now Approved in Europe to Treat Children, Adolescents with RRMS

News

Gilenya (fingolimod) was approved by the European Commission as a treatment for children and adolescents, ages 10 to 17, with relapsing-remitting multiple sclerosis (RRMS), Novartis announced. The therapy is ... Read more

November 28, 2018December 4, 2018

Artificial Intelligence May Help Reduce Dosage of Gadolinium in MRIs, Researchers Suggest

News

Artificial intelligence can help reduce the amount of gadolinium used as a contrast agent in MRI (magnetic resonance imaging) scans, preventing the agent’s potential toxicity when accumulated in body ... Read more

November 21, 2018November 21, 2018

Phase 2 Trial of NurOwn Stem Cell Therapy in Progressive MS Planned for US, BrainStorm Announces

News

BrainStorm Cell Therapeutics is planning to launch a Phase 2 clinical trial in the United States to evaluate the safety and activity of its lead cell therapy candidate, NurOwn, in ... Read more

November 20, 2018November 28, 2018

FDA Approves Generic Version of Aubagio to Treat Relapsing MS, Glenmark Pharma Says

News

The U.S. Food and Drug Administration (FDA) has approved a generic version of  Aubagio (teriflunomide) tablets at the 7 mg and 14 mg  doses marketed by Sanofi, according to the ... Read more

November 1, 2018November 6, 2018

Protein Produced by Common Gut Bacteria Can Trigger Autoimmunity, Study Suggests

News

Bacteria that reside in human gut may trigger autoimmune reactions by producing human-like proteins that mimic a naturally occurring and crucial cell protein. Researchers at Queen’s University Belfast in ... Read more

October 29, 2018October 29, 2018

Mavenclad Named ‘Rapid Uptake Product’ in UK with Goal of Speeding Its Availability in NHS

News

Mavenclad (cladribine tablets, 10 mg) was one of the seven medicinal and medical technology products selected by the Accelerated Access Collaborative (AAC) as a “rapid uptake product” — a ... Read more

October 25, 2018October 31, 2018

Stem Cells from MS, Parkinson’s Patients Voyaging to Space Station to Study Disease Impact on Brain in Microgravity

News

Stem cells from patients with Parkinson’s disease and primary progressive multiple sclerosis (PPMS) are soon to voyage into space, and be brought aboard the International Space Station so cell-to-cell interactions in ... Read more

October 19, 2018October 23, 2018

Enzyme Produced by Gut Bacteria Linked to T-cell Attacks on Myelin in Study

News

An enzyme produced by bacteria in the gut was seen to activate immune cells linked to the development and progression of multiple sclerosis, a finding that may pave the way for ... Read more

October 18, 2018October 25, 2018

#ECTRIMS2018 – Role of Brain Atrophy in MS Progression Poorly Understood by Patients, MSAA Survey Finds

News

Although brain atrophy — the loss of brain volume — is an increasingly important measure in multiple sclerosis trials and treatment outcomes, MS patients have a limited understanding of ... Read more

October 15, 2018October 15, 2018

#ECTRIMS2018 – Additional Analysis on Ozanimod Demonstrate Its Potential to Treat Relapsing MS

News

Additional analysis of clinical data from Celgene’s investigational agent ozanimod continues to demonstrate its potential to benefit patients with relapsing multiple sclerosis (MS). Findings from the Phase 3 SUNBEAM ... Read more

October 12, 2018October 12, 2018

#ECTRIMS2018 – MS Patients More Prone to Health Problems Before, After Diagnosis, Study Suggests

News

Patients with multiple sclerosis (MS) are more likely to experience health problems before they receive their formal diagnosis, as well as to experience serious non-MS-related complications after diagnosis, a ... Read more

October 10, 2018October 10, 2018

#ECTRIMS2018 — Merck KGaA to Present Latest Data on MS Portfolio

News

Merck KGaA will present the latest advances made on several of its therapies aiming to treat multiple sclerosis (MS) at the 34th Congress of the European Committee for Treatment ... Read more

October 10, 2018October 17, 2018

FDA, EMA Agree to Review Novartis Therapy Siponimod to Treat SPMS

News

Novartis is seeking U.S. and European approval of its investigational oral agent siponimod to treat adults with secondary progressive multiple sclerosis (SPMS). The U.S. Food and Drug Administration (FDA) has ... Read more

October 8, 2018October 8, 2018

UVA Scientist Awarded $5.6M by NIH to Further Study Lymph System and Brain Connection

News

Jonathan Kipnis, the researcher who discovered that lymphatic vessels are important mediators of the underlying molecular mechanism of multiple sclerosis (MS), has received the prestigious Director’s Pioneer Award from ... Read more

September 26, 2018September 26, 2018

Nyrada Identifies Novel IRAK4 Inhibitors that May Prevent Neuroinflammation

News

Nyrada, a subsidiary company of Noxopharm, discovered a set of novel compounds that can cross the blood-brain barrier and blood-nerve barriers, and inhibit a master regulator of chronic inflammation ... Read more

September 21, 2018September 26, 2018

Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report

News

Eighteen months after its entrance into the U.S. market, Genentech’s Ocrevus (ocrelizumab) has become the monoclonal antibody of choice to treat patients with multiple sclerosis (MS), according to a survey ... Read more

September 5, 2018September 5, 2018

Mavenclad Approved to Treat Highly Active Relapsing MS Patients in Ireland

News

Adults in Ireland with highly active relapsing multiple sclerosis (MS) now can be treated with Mavenclad (cladribine tablets, 10 mg), the first short-course oral treatment approved for this disease. ... Read more

August 8, 2018August 8, 2018

Quanterix’s Simoa Assay May Make Neurofilament Light Chain Useful Blood Biomarker of MS and Its Likely Progression

News

Quanterix’s ultra-sensitive Simoa assay has the potential to open new uses for the brain biomarker known as neurofilament light chain, including the possibility to detect early evidence of neurological ... Read more

August 2, 2018August 7, 2018

Potential B-cell Targeting Oral MS Treatment, PRN2246, Shows Ability to Reach Brain in Phase 1 Study

News

Results from a first-in-human study assessing the safety and early activity of PRN2246 confirmed that the oral compound can reach into the brain and spinal cord. This finding adds new ... Read more

July 31, 2018July 31, 2018

FDA to Review EMD Serono’s New Request for Approval of Cladribine for Treating Relapsing MS

News

Seven years after it first denied the request, the U.S. Food and Drug Administration accepted for review EMD Serono’s resubmitted New Drug Application (NDA) for cladribine tablets (brand name Mavenclad) ... Read more

July 27, 2018July 30, 2018

Oral DMTs Still Common 1st Therapy for New MS Patients but Ocrevus Having Impact, Market Report Says

News

Oral disease-modifying therapies (DMTs) are the most common first choice of treatment for people newly diagnosed with multiple sclerosis (MS) in the United States, an analysis reports. Antibody-based DMTs ... Read more

July 24, 2018July 25, 2018

Enzyme Key to Myelin Renewal and Nerve Cell Health Possibly Identified in Study

News

A better understanding of the processes behind a continual and healthy renewal of myelin — the fatty, protective substance wrapping nerve cell fibers — may now exist. Researchers identified ... Read more

July 17, 2018July 17, 2018

Progressive MS Patients with Considerable Disability Ably Treated with Cladribine, UK Case Study Reports

News

Cladridine may be effective in preventing disability progression and reducing damage to nerve cells in people with progressive forms of multiple sclerosis (MS), researchers suggest based on a case study of ... Read more

July 13, 2018July 17, 2018

Common Anti-Parasitic Agent Eases Motor Symptoms, Aids Remyelination in MS Mouse Model

News

A common anti-parasitic agent showed a potential to prevent inflammation and to promote nerve cell recovery — remyelination — in a mouse model of multiple sclerosis (MS). By promoting ... Read more

July 3, 2018

No Risk of MS Found in GlaxoSmithKline Vaccine for Swine Flu, Canadian Study Says

News

Protecting the public against an outbreak like the swine flu using GlaxoSmithKline‘s vaccine Arepanrix — or a similar vaccine with an AS03 adjuvant delivery system — does not increase a risk of multiple ... Read more

June 28, 2018June 28, 2018

Probe That Acts as PET Scan Tracer May Give Glimpse into Gene Therapy’s Effects on Brain

News

A radioactive probe that might enable imaging tools to effectively monitor what a gene therapy is doing in the brain — important in treating diseases like multiple sclerosis with ... Read more

June 21, 2018June 21, 2018

#EAN2018 – Pupil Response to Light Linked to RRMS Duration and Severity in Study

News

Measuring the response of the pupil to light stimulating the eye is a non-invasive and easy way to assess multiple sclerosis (MS) severity and progression, researchers report. A clinical ... Read more